stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Book value per share
Summit Therapeutics PLC's book value per share at the end of fiscal 2025 was 0.9×, up 62.9% from 0.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 0.8×. Over the past ten years it has ranged from −0.4× (fiscal 2017) to 3.3× (fiscal 2019); the current reading is higher than 60% of that period. Summit Therapeutics PLC ranks 373rd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 0.9× | 62.88% |
| FY2024 | 0.5× | 331.42% |
| FY2023 | 0.1× | (80.86%) |
| FY2022 | 0.7× | 3.61% |
| FY2021 | 0.6× | (44.67%) |
| FY2020 | 1.1× | (52.43%) |
| FY2019 | 2.4× | (27.05%) |
| FY2019 | 3.3× | — |
| FY2018 | 0.0× | — |
| FY2018 | 1.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 0.8× | 15.00% |
| Mar 2026 | 0.7× | (20.11%) |
| Dec 2025 | 0.9× | 240.76% |
| Sep 2025 | 0.3× | (25.99%) |
| 44 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 64.8× |
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| ASND Ascendis Pharma A/S compare | 26.0× |
| PCVX Vaxcyte, Inc. compare | 19.1× |
| KYMR Kymera Therapeutics, Inc. compare | 16.1× |
| TECH Bio-Techne Corp compare | 13.5× |
| SMMT Summit Therapeutics PLC | 0.8× |
| HALO Halozyme Therapeutics, Inc. compare | −0.5× |
| BBIO BridgeBio Pharma, Inc. compare | −8.4× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement